Table 5.
Effects of sitagliptin in SCE and PI in cultured human lymphocytes
| Test substance (µg/ml) | Concentartion (µg/ml) | Period | S9 mix | M1 | M2 | M3 | Min–max SCE | Total SCE | SCE/cell ± SE | PI ± SE |
|---|---|---|---|---|---|---|---|---|---|---|
| DMSO | 1 | 24 h | – | 20 | 137 | 243 | 159–194 | 698 | 174.5 ± 7.31 | 2.56 ± 0.06 |
| MMC | 0.16 | 24 h | – | 28 | 256 | 116 | 975–1429 | 4735 | 1183.8 ± 111.69 | 2.22 ± 0.03 |
| Vildagliptin | 125 | 24 h | – | 38 | 122 | 250 | 148–201 | 694 | 173.5 ± 12.55 | 2.58 ± 0.04 |
| Vildagliptin | 250 | 24 h | – | 15 | 100 | 285 | 145–208 | 656 | 164 ± 14.75 | 2.68 ± 0.02 |
| Vildagliptin | 500 | 24 h | – | 16 | 118 | 266 | 119–215 | 615 | 153.75 ± 13.42 | 2.63 ± 0.04 |
| DMSO | 1 | 48 h | – | 42 | 143 | 215 | 119–215 | 699 | 174.75 ± 20.27 | 2.43 ± 0.06 |
| MMC | 0.16 | 48 h | – | 108 | 290 | 2 | 2380–4049 | 11988 | 2997 ± 380.60 | 1.74 ± 0.13 |
| Vildagliptin | 125 | 48 h | – | 24 | 149 | 227 | 160–199 | 703 | 175.75 ± 9.20 | 2.51 ± 0.06 |
| Vildagliptin | 250 | 48 h | – | 18 | 162 | 220 | 141–237 | 720 | 180 ± 20.47 | 2.51 ± 0.01 |
| Vildagliptin | 500 | 48 h | – | 27 | 156 | 217 | 93–243 | 752 | 188 ± 33.54 | 2.48 ± 0.06 |
| DMSO | 1 | S9 mix | + | 44 | 324 | 32 | 115–174 | 556 | 139 ± 14.16 | 1.97 ± 0.02 |
| CP | 45 | S9 mix | + | 100 | 297 | 3 | 532–628 | 2310 | 577.5 ± 22.14 | 1.76 ± 0.02 |
| Vildagliptin | 125 | S9 mix | + | 49 | 328 | 23 | 136–188 | 636 | 159 ± 12.38 | 1.94 ± 0.02 |
| Vildagliptin | 250 | S9 mix | + | 51 | 327 | 22 | 126–185 | 587 | 146.75 ± 13.09 | 1.93 ± 0.02 |
| Vildagliptin | 500 | S9 mix | + | 45 | 333 | 22 | 127–181 | 626 | 156.5 ± 11.71 | 1.94 ± 0.02 |
| DMSO | 1 | 24 h | – | 35 | 152 | 213 | 83–225 | 646 | 161.50 ± 35.72 | 2.45 ± 0.10 |
| MMC | 0.16 | 24 h | – | 105 | 229 | 66 | 857–1252 | 4264 | 1073.5086.87 | 1.90 ± 0.16 |
| Sitagliptin | 250 | 24 h | – | 63 | 176 | 161 | 121–224 | 631 | 157.75 ± 22.98 | 2.25 ± 0.19 |
| Sitagliptin | 500 | 24 h | – | 62 | 151 | 187 | 94–231 | 717 | 179.25 ± 29.73 | 2.31 ± 0.12 |
| Sitagliptin | 1000 | 24 h | – | 59 | 167 | 174 | 76–270 | 678 | 169.50 ± 40.75 | 2.29 ± 0.12 |
| DMSO | 1 | 48 h | – | 53 | 150 | 197 | 101–267 | 716 | 179.00 ± 39.66 | 2.36 ± 0.19 |
| MMC | 0.16 | 48 h | – | 129 | 263 | 8 | 1749–3751 | 10570 | 2642.50 ± 413.59 | 1.70 ± 0.13 |
| Sitagliptin | 250 | 48 h | – | 63 | 212 | 128 | 117–230 | 732 | 183.00 ± 26.23 | 2.18 ± 0.13 |
| Sitagliptin | 500 | 48 h | – | 57 | 240 | 103 | 91–207 | 628 | 157.00 ± 25.34 | 2.12 ± 0.03 |
| Sitagliptin | 1000 | 48 h | – | 173 | 206 | 21 | 203–299 | 1036 | 259.00 ± 22.57 | 1.62 ± 0.08* |
| DMSO | 1 | S9 mix | + | 59 | 310 | 31 | 114–174 | 528 | 132.00 ± 14.17 | 1.93 ± 0.07 |
| CP | 45 | S9 mix | + | 72 | 325 | 3 | 500–676 | 2391 | 597.75 ± 39.46 | 1.83 ± 0.05 |
| Sitagliptin | 250 | S9 mix | + | 44 | 334 | 22 | 127–216 | 632 | 158.00 ± 20.32 | 1.95 ± 0.04 |
| Sitagliptin | 500 | S9 mix | + | 39 | 348 | 13 | 138–168 | 626 | 156.50 ± 7.23 | 1.94 ± 0.03 |
| Sitagliptin | 1000 | S9 mix | + | 82 | 293 | 25 | 115–189 | 628 | 157.00 ± 15.81 | 1.86 ± 0.05 |
* Significantly different from the solvent control p < 0.05 (ANOVA)